|
Synonyms: CD37-SMIP [8] | TRU-016 | TRU016
Compound class:
Antibody
Comment: Otlertuzumab (TRU-016) is a monospecific, humanized anti-CD37 antibody-like protein that is being investigated as a clinical therapeutic for various form of lymphoma [4,6-7]. Otlertuzumab was developed using Aptevo's modular ADAPTIRTM platform.
|
| No information available. |
Summary of Clinical Use  |
| Preliminary evidence of clinical efficacy in a small number of patients with highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma has been reported [4]- see NCT00614042. A Phase 1b study of TRU-016 plus other biological or small molecule chemotherapeutic drugs (NCT01644253) is under way (May 2018). |
| Mechanism Of Action and Pharmacodynamic Effects |
| Otlertuzumab induces apoptosis directly via binding to the CD37 molecule, utilising a mechanism that is caspase-independent [3,8]. Preclinical in vitro and in vivo studies show that otlertuzumab mediates apoptosis and Fc‐dependent cellular toxicity against primary CLL and NHL cells [8]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00614042 | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | Phase 1 Interventional | Aptevo Therapeutics | ||
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | Phase 1 Interventional | Aptevo Therapeutics | ||
